Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR plus ) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials.

被引：0
|
作者：
Pagani, Olivia
Regan, Meredith M.
Walley, Barbara
Fleming, Gini F.
Colleoni, Marco
Lang, Istvan
Gomez, Henry Leonidas
Tondini, Carlo
Burstein, Harold J.
Perez, Edith A.
Ciruelos, Eva
Stearns, Vered
Bonnefoi, Herve R.
Martino, Silvana
Geyer, Charles E.
Rabaglio-Poretti, Manuela
Coates, Alan S.
Gelber, Richard D.
Goldhirsch, Aron
Francis, Prudence A.
机构：
[1] SAKK, Inst Oncol Southern Switzerland, Lugano Viganello, Switzerland
[2] IBCSG, Lugano Viganello, Switzerland
[3] Dana Farber Canc Inst, IBCSG Stat Ctr, Boston, MA 02115 USA
[4] NCIC Clin Trials Grp, Kingston, ON, Canada
[5] Univ Chicago, Med Ctr & Alliance, Chicago, IL 60637 USA
[6] European Inst Oncol, Milan, Italy
[7] IBCSG, Milan, Italy
[8] Natl Inst Oncol, Budapest, Hungary
[9] Inst Natl Enfermedades Neoplas, Lima, Peru
[10] IBCSG, Lima, Peru
[11] Osp Papa Giovanni XXIII, Bergamo, Italy
[12] Dana Farber Canc Inst & Alliance, Boston, MA USA
[13] Mayo Clin & Alliance, Jacksonville, FL USA
[14] Univ Hosp 12 Octubre, Madrid, Spain
[15] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[16] ECOG, Baltimore, MD USA
[17] Bergonie Inst, Bordeaux, France
[18] EORTC, Bordeaux, France
[19] Angeles Clin & Res Inst, Santa Monica, CA USA
[20] SWOG, Santa Monica, CA USA
[21] Virginia Commonwealth Univ, Massey Canc Ctr, Sch Med, Richmond, VA USA
[22] NRG Oncol, Richmond, VA USA
[23] Inst Med Oncol, Bern, Switzerland
[24] Int Breast Canc Study Grp, Bern, Switzerland
[25] ANZBCTG, Peter MacCallurn Canc Ctr, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA1
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Long-term comparisons of the efficacy, safety, and pregnancy outcomes of adjuvant tamoxifen plus ovarian function suppression in premenopausal Han and Zhuang Chinese patients with hormone receptor-positive early breast cancer
    Tang, Shicong
    Zhang, Qiong
    Tang, Xianghui
    Chen, Dong
    Zhang, Fan
    Liu, Jianlun
    Wei, Wei
    Liu, Dequan
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2019, 47 (02) : 641 - 652
  • [22] Adjuvant!© Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer
    Robert J. Paridaens
    Shari Gelber
    Bernard F. Cole
    Richard D. Gelber
    Beat Thürlimann
    Karen N. Price
    Stig B. Holmberg
    Diana Crivellari
    Alan S. Coates
    Aron Goldhirsch
    Breast Cancer Research and Treatment, 2010, 123 : 303 - 310
  • [23] Adjuvant© Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer
    Paridaens, Robert J.
    Gelber, Shari
    Cole, Bernard F.
    Gelber, Richard D.
    Thuerlimann, Beat
    Price, Karen N.
    Holmberg, Stig B.
    Crivellari, Diana
    Coates, Alan S.
    Goldhirsch, Aron
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 123 (01) : 303 - 310
  • [24] Randomized comparison of adjuvant toremifene (Tor) versus tamoxifen (Tam) for postmenopausal women with node-positive (N plus ), estrogen receptor-positive (ER plus ) early stage breast cancer
    不详
    BREAST, 2005, 14 : S38 - S38
  • [25] Phase III Comparison of Tamoxifen Versus Tamoxifen Plus Ovarian Function Suppression in Premenopausal Women With Node-Negative, Hormone Receptor-Positive Breast Cancer (E-3193, INT-0142): A Trial of the Eastern Cooperative Oncology Group
    Tevaarwerk, Amye J.
    Wang, Molin
    Zhao, Fengmin
    Fetting, John H.
    Cella, David
    Wagner, Lynne I.
    Martino, Silvana
    Ingle, James N.
    Sparano, Joseph A.
    Solin, Lawrence J.
    Wood, William C.
    Robert, Nicholas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (35) : 3948 - U237
  • [26] Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials
    Bernhard, Juerg
    Luo, Weixiu
    Ribi, Karin
    Colleoni, Marco
    Burstein, Harold J.
    Tondini, Carlo
    Pinotti, Graziella
    Spazzapan, Simon
    Ruhstaller, Thomas
    Puglisi, Fabio
    Pavesi, Lorenzo
    Parmar, Vani
    Regan, Meredith M.
    Pagani, Olivia
    Fleming, Gini F.
    Francis, Prudence A.
    Price, Karen N.
    Coates, Alan S.
    Gelber, Richard D.
    Goldhirsch, Aron
    Walley, Barbara A.
    LANCET ONCOLOGY, 2015, 16 (07): : 848 - 858
  • [27] CYP19A1 and ESR1 polymorphisms and selected early-onset side effects during combined endocrine therapy in the IBCSG TEXT trial for premenopausal women with hormone receptor-positive (HR plus ) early breast cancer
    Johansson, Harriet
    Gray, Kathryn P.
    Pagani, Olivia
    Regan, Meredith M.
    Viale, Giuseppe
    Aristarco, Valentina
    Macis, Debora
    Puccio, Antonella
    Roux, Susanne
    Maibach, Rudolf
    Colleoni, Marco
    Rabaglio-Poretti, Manuela
    Coates, Alan S.
    Gelber, Richard D.
    Goldhirsch, Aron
    Kammler, Roswitha
    Bonanni, Bernardo
    Walley, Barbara A.
    CANCER RESEARCH, 2015, 75
  • [28] A Pharmaco-Economic Analysis of Tamoxifen (T) vs. Aromatase Inhibitors (AI) in Adjuvant Treatment of Postmenopausal (PoM) Women (W) with Hormone Receptor Positive (HRP) Breast Cancer (BC)
    Sehgal, R.
    Lark, C.
    CANCER RESEARCH, 2010, 70
  • [29] Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): additional results from the MONALEESA-7 trial
    Harbeck, N.
    Vazquez, R. Villanueva
    Tripathy, D.
    Lu, Y.
    De Laurentiis, M.
    Kuemmel, S.
    Taylor, D.
    Bardia, A.
    Hurvitz, S.
    Chow, L.
    Im, S.
    Franke, F.
    Hughes, G.
    Miller, M.
    Kong, O.
    Chandiwana, D.
    Colleoni, M.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S3 - S3
  • [30] Adjuvant study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR plus ) early breast cancer (EBC), who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity (AMEERA-6).
    Meyskens, Thomas
    Metzger, Otto
    Poncet, Coralie
    Goulioti, Theodora
    Xenophontos, Eleni
    Carey, Lisa A.
    Wang, Lei
    Rossi, Giovanna
    Gilham, Leslie
    De Swert, Heidi
    Casas-Martin, Jose
    Attieh, Elham
    Arahmani, Amal
    De Meulemeester, Laura
    Partridge, Ann H.
    Herold, Christina Isabella
    Paux, Gautier
    Dueck, Amylou C.
    Brain, Etienne
    Cameron, David A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345